PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Naval Daver, MD, Amir T. Fathi, MD - The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes Oct 28, 2022

Show notes

Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

Brendon M. Stiles, MD - Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings Oct 28, 2022

Show notes

Go online to PeerView.com/WRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approximately 40% of patients with early-stage lung cancer experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Management of patients with NSCLC should be individualized based on a number of factors, including the molecular profile of the patient’s tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have prompted strong interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. Early findings from studies in the neoadjuvant setting are beginning to emerge now as well, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. As part of the multidisciplinary team, thoracic surgeons play an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational video, based on a recent live symposium, provides an essential overview of the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings, as well as practical advice for optimal integration of targeted therapies in practice or as part of a clinical trial. Multidisciplinary discussions on the new practice-changing data highlight important implications for the surgeon–oncologist partnership, utilizing EGFR-targeted therapy as part of multimodal management of patients with resectable NSCLC with the goal of improving outcomes and quality of life. Upon completion of this activity, participants should be better able to: Review the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and importance of identifying patients who might benefit from these therapies in perioperative settings; Apply the latest evidence and guidelines to identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches; Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Professor Jacob P. Thyssen - Using Biologics to Manage Moderate to Severe Atopic Dermatitis: Compare Your Approach With Experts From Around the World Oct 28, 2022

Show notes

Go online to PeerView.com/RBZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis is a chronically relapsing skin disease that often begins in early childhood and can persist into adulthood, having a detrimental effect on the lives of patients and their families throughout the lifespan. In this activity, based on a recent live web broadcast, our global experts provide both pediatric and adult dermatologists, allergy/immunology specialists, and other specialty advanced practice providers around the world greater insight into the assessment of disease severity, the use of targeted biologic therapy, and the importance of patient engagement and shared decision-making in the management of atopic dermatitis. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD); Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines; Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy; Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care

Marina Chiara Garassino, MD - Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer Oct 28, 2022

Show notes

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView’s latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Guillermo Garcia-Manero, MD; Gail J. Roboz, MD - The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes Oct 20, 2022

Show notes

Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Professor Aleix Prat, MD, PhD - Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients Oct 20, 2022

Show notes

Go online to PeerView.com/FGB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. HER2-targeting therapies have led to remarkable improvements in patients with HER2-positive early and advanced breast cancer. Recently, novel antibody–drug conjugates (ADCs) and other HER2-targeting therapies have also demonstrated impressive activity in patients with HER2-low breast cancer, who account for approximately 40%-50% of patients with breast cancer and are a population with a high unmet medical need. The concepts of how to best define and test for HER2-low breast cancer are evolving, but the modern HER2-targeting agents offer new hope for dramatically improved outcomes in patients who currently have limited options. This PeerView educational video, based on a recent live symposium, explores the biology and foundational concepts of HER2-low breast cancer, highlights the rationale for and data supporting the use of HER2-targeted therapies in HER2-low breast cancer, assesses emerging approaches for identifying patients with HER2-low breast cancer who could benefit from HER2-targeted therapies, and clarifies how to best incorporate these therapies into practice in real-world settings. Clinical case scenarios are also used to provide useful guidance for testing and treatment of patients with HER2-low breast cancer. Upon completion of this activity, participants should be better able to: Explain the biologic rationale and clinical evidence on the growing role of HER2-targeting therapies in the treatment of patients with HER2-low breast cancer; Apply standard and emerging testing approaches to identify patients with HER2-low breast cancer to determine their eligibility for novel HER2-targeted therapies; Integrate individualized management plans that incorporate a collaborative and coordinated multidisciplinary team-based approach to care in accordance with the latest treatment guidelines and recommendations for patients with lower spectrum HER2-expressing breast cancer in the context of clinical practice or clinical trials

Sara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer Oct 20, 2022

Show notes

Go online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events. Upon completion of this activity, participants should be better able to: Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer; Describe disease-, treatment-, management-, patient-related, and other relevant factors that can impact adherence and persistence to oral therapies among patients with HR+/HER2- early breast cancer, including patient perceptions and education, adverse events, care coordination, and collaboration; Apply appropriate strategies to identify, treat, and monitor patients with HR+/HER2- early breast cancer receiving oral CDK4/6 inhibitor therapies to prevent/manage treatment- related adverse events (TRAEs); Integrate effective team-based communication approaches, including shared decision- making, to appropriately educate and engage patients on CDK4/6 inhibitors about TRAEs, collaboratively establish and achieve treatment goals, and maximize adherence and persistence

Jay H. Shubrook, DO, FAAFP, FACOFP - Tools of the Trade: A Practical Guide to Managing NASH Oct 20, 2022

Show notes

Go online to PeerView.com/ACR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses how to utilize the American Gastroenterological Association’s Clinical Care Pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Upon completion of this activity, participants should be better able to: List the disease pathways and mechanisms that define NASH as a metabolic disease; Identify the pathophysiology and role of GLP-1 as a therapeutic target in NASH; Differentially diagnose NASH in a timely manner; Integrate current and emerging agents into early management plans for patients with NASH based on the AGA NASH Clinical Care Pathway

Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy Oct 20, 2022

Show notes

Go online to PeerView.com/TJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP. In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

Javier Cortes, MD, PhD - SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting Therapies Oct 19, 2022

Show notes

Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected